- Home
- ABUS vs ACIC Comparison
ABUS vs ACIC Comparison
Compare ABUS & ACIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- ACIC
- Stock Information
- Founded
- ABUS N/A
- ACIC 1999
- Country
- ABUS United States
- ACIC United States
- Employees
- ABUS N/A
- ACIC N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- ACIC Property-Casualty Insurers
- Sector
- ABUS Health Care
- ACIC Finance
- Exchange
- ABUS Nasdaq
- ACIC Nasdaq
- Market Cap
- ABUS 725.9M
- ACIC 644.2M
- IPO Year
- ABUS N/A
- ACIC N/A
- Fundamental
- Price
- ABUS $3.46
- ACIC $13.32
- Analyst Decision
- ABUS Strong Buy
- ACIC Buy
- Analyst Count
- ABUS 4
- ACIC 1
- Target Price
- ABUS $5.50
- ACIC $16.00
- AVG Volume (30 Days)
- ABUS 837.4K
- ACIC 204.0K
- Earning Date
- ABUS 11-06-2024
- ACIC 11-06-2024
- Dividend Yield
- ABUS N/A
- ACIC N/A
- EPS Growth
- ABUS N/A
- ACIC N/A
- EPS
- ABUS N/A
- ACIC 1.76
- Revenue
- ABUS $6,742,000.00
- ACIC $290,784,000.00
- Revenue This Year
- ABUS N/A
- ACIC N/A
- Revenue Next Year
- ABUS N/A
- ACIC $12.98
- P/E Ratio
- ABUS N/A
- ACIC $7.57
- Revenue Growth
- ABUS N/A
- ACIC 1.02
- 52 Week Low
- ABUS $1.79
- ACIC $8.10
- 52 Week High
- ABUS $4.72
- ACIC $14.38
- Technical
- Relative Strength Index (RSI)
- ABUS 30.63
- ACIC 61.61
- Support Level
- ABUS $3.42
- ACIC $12.70
- Resistance Level
- ABUS $3.81
- ACIC $13.31
- Average True Range (ATR)
- ABUS 0.16
- ACIC 0.51
- MACD
- ABUS -0.04
- ACIC -0.02
- Stochastic Oscillator
- ABUS 7.41
- ACIC 87.95
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary. The company has two segments namely: Commercial Lines Business and Personal Lines Business. It derives maximum revenue from Commercial Lines Business Segment.